Legal & General Group
ZBIO

Legal & General Group’s Zenas BioPharma ZBIO Stock Holding History

Legal & General Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$508K Buy
20,023
+9,591
+92% +$191K ﹤0.01% 2397
2026
Q1 		$204K Sell
10,432
-2,595
-20% -$58.2K ﹤0.01% 2536
2025
Q4 		$473K Buy
13,027
+11,673
+862% +$384K ﹤0.01% 2449
2025
Q3 		$30K Sell
1,354
-194
-13% -$3.16K ﹤0.01% 2890
2025
Q2 		$15K Buy
1,548
+29
+2% +$282 ﹤0.01% 3131
2025
Q1 		$12K Hold
1,519
– – ﹤0.01% 3116
2024
Q4 		$12.4K Buy
+1,519
New +$23.7K ﹤0.01% 3200

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Legal & General Group's ZBIO Position: Q2 2026 in Review

Legal & General Group increased its Zenas BioPharma (ZBIO) stake by 92% in Q2 2026, buying an estimated $191K and bringing the position to 20,023 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #2397.

Legal & General Group first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Legal & General Group held 20,023 shares of Zenas BioPharma worth $508K as of Q2 2026.
  • Legal & General Group bought 9,591 Zenas BioPharma shares in Q2 2026, an estimated $191K.
  • Zenas BioPharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2397 holding.
  • Legal & General Group first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.